Physician profile
Richard W Mcclain
NPI 1851568802
$3,895.68
in general payments reported to CMS, 2019-2025
21 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $85.91 · 2022: $150 · 2023: $1,116 · 2024: $1,057 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,680 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.08 |
| Education | $366.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $906.30 | 2019-2025 | |
| Genzyme Corporation | $677.40 | 2019-2025 | |
| Janssen Biotech, INC. | $564.03 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $274.75 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $236.94 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $172.66 | 2019-2023 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $171.67 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $147.76 | 2019-2025 | |
| Amgen INC. | $130.45 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $105.39 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $103.75 | 2019-2025 | Nemluvio |
| Genentech USA, INC. | $89.87 | 2019 | |
| Pfizer INC. | $79.85 | 2019-2020 | |
| Incyte Corporation | $70.25 | 2023-2024 | Opzelura |
| Celgene Corporation | $43.86 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $39.17 | 2025 | Sofdra |
| Leo Pharma INC. | $25.01 | 2025 | Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.43 | 2023 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $11.08 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.05 | 2019 | |
| Prugen, INC. Pharmaceuticals | $10.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.